Skip to main content
  • Comprehensive Ophthalmology, Retina/Vitreous

    A weekly roundup of ophthalmic news from around the web.

    Deep-learning models may deduce retinal abnormalities from OCT images. Investigators in Italy used more than 10,500 anonymized OCT foveal scans from both healthy and pathologic eyes to create deep-learning models for identifying signs of retinal abnormalities (e.g., macular hole, drusen, epiretinal membrane). Nine models were developed to assess these scans, based on Visual Geometry Group 16 architecture, and each accurately detected all abnormal retinal signs. These findings could be used to further the development of deep-learning models for diagnosing other ocular pathologies. Scientific Reports

    Do race and gender impact your odds of matching into an ophthalmology fellowship? It depends, according to San Francisco Match’s recent review of data from the 2021 ophthalmology clinical fellowship match season. Of all fellowship applicants in 2021, 43% were women and 13% identified as being from a group underrepresented in medicine (URiM): Black, Hispanic, Native Hawaiian, Native American, or multiracial. While 71% of the female applicants matched into subspeciality fellowships, only 55% of the URiM applicants matched into subspeciality fellowships, lower rates than Asian (78%) or White (69%) applicants. Female and URiM applicants were found to be the most underrepresented in retina fellowships. The authors conclude that these findings “may provide valuable information to fellowship programs and subspecialty societies that are striving to increase representation and diversity.” JAMA Ophthalmology

    University of Southern California startup receives funding for research into a novel geographic atrophy treatment. Regenerative Patch Technologies received a $12.4 million grant from the California Institute for Regenerative Medicine to move forward with a phase 2b trial of a subretinal stem cell implant under development to treat geographic atrophy (GA). This grant is paired with $9 million in additional funding from USC Research and Innovation and the Marcus Foundation. The clinical trial is expected to enroll 24 patients with vision loss due to GA. University of Southern California